| Wang, Zheng |
NCT06387368: Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer |
|
|
| Not yet recruiting | 4 | 488 | NA | Huaier Granule, Z20000109#NMPA Approval Number#, Capecitabine, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Non-resectable | 03/28 | 08/28 | | |
NCT06368063: The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer |
|
|
| Recruiting | 4 | 642 | RoW | Huaier granule, Z20000109#NMPA Approval Number#, chemotherapy drugs, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Resectable | 03/26 | 03/28 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT04521153: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2/3 | 294 | RoW | Camrelizumab, Apatinib Mesylate, TACE treatment, Radical surgery | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy | 07/25 | 03/26 | | |
| Recruiting | 2 | 30 | RoW | Niraparib | Tianjin Huanhu Hospital | Recurrent Glioblastoma | 01/22 | 01/23 | | |
NCT04295317: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery |
|
|
| Active, not recruiting | 2 | 65 | RoW | PD-1 blocking antibody SHR-1210, Capecitabine | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 06/25 | 06/25 | | |
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 120 | RoW | TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-alcoholic Steatohepatitis | 12/26 | 12/27 | | |
| Recruiting | 2 | 116 | RoW | Placebo, TQA3334 Tablet, Nucleoside (acid) analogs (NAs) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Hepatitis B | 12/25 | 06/26 | | |
NCT02802124: Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma |
|
|
| Terminated | N/A | 30 | RoW | carbon-ion radiotherapy for tumor away from GI, carbon-ion radiotherapy for tumor adjacent to GI | Shanghai Proton and Heavy Ion Center | Hepatocellular Carcinoma | 10/23 | 10/23 | | |
NCT05229133: Efficacy and Safety of CLEAR in Myopia and Astigmatism in Chinese Population |
|
|
| Recruiting | N/A | 215 | RoW | CLEAR, Corneal lenticule extraction for advanced refractive correction | Ziemer Ophthalmic Systems AG, Tigermed Consulting Co., Ltd | Myopic Astigmatism | 03/23 | 03/23 | | |
NCT03573791: Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer |
|
|
| Recruiting | N/A | 152 | RoW | | Wuhan Union Hospital, China | Rectal Cancer, Cancer of Rectum, Cancer of the Rectum, Neoplasms, Rectal, Rectal Tumors, Rectum Cancer, Rectum Neoplasms | 05/25 | 05/26 | | |
| Recruiting | N/A | 5000 | RoW | Blood test | Wuhan Union Hospital, China | Neoplasms, Cancer | 11/24 | 12/24 | | |
| Recruiting | N/A | 48 | RoW | Carbon ion radiotherapy | Shanghai Proton and Heavy Ion Center | Pancreatic Cancer Non-resectable | 12/25 | 12/26 | | |
| Not yet recruiting | N/A | 100 | RoW | Molecular Profiling & drug testing in tumor organoids and PDXs | Wuhan Union Hospital, China | Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma | 07/26 | 07/26 | | |
| Zhu, Feng |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
TQC3721-II-03, NCT06527144: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 240 | RoW | 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pulmonary Disease, Chronic Obstructive | 02/25 | 12/25 | | |
TQC2731-Ⅱ-04, NCT06707883: A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 258 | RoW | TQC2731 injection, TQC2731 Placebo | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Chronic Obstructive Pulmonary Disease | 12/26 | 09/27 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
TQB3909-Ib/II-02, NCT05959694: A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . |
|
|
| Recruiting | 1/2 | 107 | RoW | TQB3909 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/25 | 06/26 | | |
NCT03689439: Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer? (ECTOP-1006) |
|
|
| Completed | N/A | 1000 | RoW | bone scintigraphy | Fudan University | Bone Metastases | 11/21 | 11/22 | | |
NCT05855395: The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19 |
|
|
| Recruiting | N/A | 5815 | RoW | Glucocorticoid, dexamethasone, prednisone, methylprednisolone | Huashan Hospital | COVID-19 | 05/24 | 12/24 | | |
NCT05850572: A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Depression |
|
|
| Not yet recruiting | N/A | 100 | NA | Fecal microbiota transplantation(FMT), Placebo | First Affiliated Hospital Xi'an Jiaotong University | Depression | 12/25 | 12/26 | | |
NCT05850585: A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Schizophrenia |
|
|
| Not yet recruiting | N/A | 100 | NA | Fecal microbiota transplantation(FMT), Placebo | First Affiliated Hospital Xi'an Jiaotong University | Schizophrenia | 12/25 | 12/26 | | |
| Qiu, Yuanwang |
NCT04883177: Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101) |
|
|
| Completed | N/A | 1000 | RoW | | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Huashan Hospital, The Sixth People's Hospital of Shenyang City, Xingtai City People's Hospital, Jinchang Central Hospital, Baoding People's Hospital, The Third People's Hospital of Zhenjiang City, Shanxi Bethune Hospital, Wuhan Jinyintan Hospital, Jincheng People's Hospital, The Third People's Hospital of Tibet Autonomous Region, People's Hospital of Ningxia Hui Autonomous Region, Fuling Central Hospital of Chongqing City, Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region, The Central Hospital of Lishui City, The Third People's Hospital of Linfen City, Yibin First People's Hospital, Jingzhou Central Hospital, Wuxi Fifth People's Hospital, Qingyang People's Hospital, The First Affiliated Hospital of Anhui Medical University, Beilun Hospital of Traditional Chinese Medicine, Henan Provincial People's Hospital, Qingdao Sixth People's Hospital, The First Affiliated Hospital of Xiamen University, Shandong Provincial Hospital, Beijing YouAn Hospital, The First People's Hospital of Taicang, The Third People's Hospital of Taiyuan, Tianjin Second People's Hospital, Tianjin Third Central Hospital, Qishan Hospital of Yantai City, Affiliated Hospital of Yunnan University, The First People's Hospital of Yunnan, The Fourth Affiliated Hospital of Zhejiang University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Chongqing Medical University | COVID-19, Liver Disease, Vaccine Reaction | 01/22 | 05/22 | | |
Promote, NCT05797714: The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT. |
|
|
| Active, not recruiting | N/A | 200 | RoW | Tenofovir Amibufenamide（TMF）, HengMu | Ruijin Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | HBV Infection, Chronic Hepatitis b | 06/24 | 04/26 | | |
| Wu, Hangyuan |
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. |
|
|
| Completed | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 10/24 | 10/24 | | |
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis |
|
|
| Recruiting | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 06/28 | 10/28 | | |
| Jiang, Jianzhong |
TQC3721-II-03, NCT06527144: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 240 | RoW | 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pulmonary Disease, Chronic Obstructive | 02/25 | 12/25 | | |
